Key Takeaways:
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion in cash, adding two potential blockbuster rare-disease therapies to its pipeline.
Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 a share in cash, or about $10 billion in equity value, the companies said Monday. The deal, which values Crinetics at roughly $8.8 billion net of estimated cash acquired, gives Vertex access to PALSONIFY, a once-daily oral therapy for acromegaly approved by the US Food and Drug Administration in September 2025, and atumelnant, a late-stage candidate for congenital adrenal hyperplasia.
"Vertex can build on the strong momentum of the PALSONIFY launch by applying our experience in commercializing medicines for rare genetic diseases," said Reshma Kewalramani, chief executive officer of Vertex. She also highlighted atumelnant's potential to "transform the treatment landscape for CAH, setting a new standard of care where patients do not have to choose between managing their excess adrenal androgens and enduring the side effects of high-dose steroids."
PALSONIFY, known generically as paltusotine, is the first and only once-daily oral treatment for acromegaly, a rare hormonal disorder affecting about 20,000 diagnosed people in the US. The drug has shown early commercial momentum since its launch, with expanding prescribing activity and growing reimbursement coverage, according to the companies. Atumelnant is in Phase 3 development for classic CAH, which affects about 17,000 addressable patients in the US, and has also entered a Phase 1/2b trial for ACTH-dependent Cushing's syndrome. In Phase 2 studies, patients taking atumelnant achieved near-normalization of excess androgen levels on physiologic replacement doses of glucocorticoids.
The acquisition is expected to contribute immediately to Vertex's revenue growth through PALSONIFY sales, with the companies projecting the two drugs could generate more than $5 billion in combined annual revenue at peak. Vertex expects the deal to become accretive to non-GAAP operating income by 2029. The transaction was approved by both companies' boards and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.
Vertex plans to finance the acquisition using cash on hand and debt, supported by $4.5 billion in fully committed bridge financing from Bank of America and Morgan Stanley Senior Funding. Morgan Stanley and Lazard advised Vertex, while J.P. Morgan Securities and Leerink Partners advised Crinetics. Kirkland & Ellis served as legal counsel to Vertex, with Paul, Weiss, Rifkind, Wharton & Garrison and Morrison Foerster advising Crinetics.
The deal marks Vertex's latest move to diversify beyond its core cystic fibrosis franchise, which has generated billions in annual revenue from drugs including Trikafta. The company has been expanding into other serious diseases with well-understood causal biology, including sickle cell disease, type 1 diabetes and IgA nephropathy. Adding Crinetics' endocrine-focused pipeline gives Vertex a foothold in two rare-disease markets with limited treatment options and significant unmet need, where patients have historically relied on injectable therapies or high-dose steroids with serious side effects.
This article is for informational purposes only and does not constitute investment advice.
